We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

By LabMedica International staff writers
Posted on 04 Feb 2026

Alzheimer’s disease affects approximately 6. More...

7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests that imbalances in the gut microbiome—known as dysbiosis—may contribute to the onset and progression of mild cognitive impairment (MCI) and Alzheimer’s disease.

Researchers are increasingly focused on the microbiota–gut–brain axis, a complex network linking the gut, immune system, and brain. Disruptions in this system are thought to promote neuroinflammation, leading to damage of nerve cells and potentially accelerating cognitive decline associated with Alzheimer’s disease. New research has revealed reproducible bacterial and functional signatures linking gut microbiome dysbiosis to MCI and Alzheimer’s disease.

George Washington University (Washington, DC, USA) researchers analyzed 58 human studies published through February 2023, constituting the most comprehensive human-only review in this area. Published January 22, 2026 in Alzheimer’s & Dementia, the work assessed microbiome composition, diversity, and predicted function. 

Across multiple studies, people with mild cognitive impairment and Alzheimer’s disease consistently exhibited gut microbiota profiles that differed from those of cognitively healthy older adults. Alzheimer’s disease was associated with higher levels of certain bacterial groups, particularly the phyla Pseudomonadota and Actinomycetota. In addition, some individuals with Alzheimer’s disease showed reduced gut microbial diversity, meaning they had fewer types of bacteria than typically observed.

The types and relative abundance of gut bacteria differ among people with MCI, Alzheimer’s disease, and cognitively healthy individuals, suggesting distinct microbiome signatures at different stages of cognitive decline. In people with Alzheimer’s disease, functional alterations in gut bacteria have also been observed, including reduced activity in pathways related to energy production and immune function.

Although the review does not establish a cause-and-effect relationship, its findings are consistent with broader evidence indicating that diets high in fiber may promote a healthier gut microbiome, with possible downstream benefits for inflammation and brain health.

“While these early, largely observational results are encouraging, we need clinical trials to determine whether microbiome-targeted interventions can meaningfully alter disease trajectories. These trials are already underway in our lab and labs around the world.” said lead researcher Leigh Frame, associate professor in the George Washington University School of Medicine and Health Sciences. 

Related Links
GW School of Medicine & Health Science


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Senior researcher Annikka Polster collaborated with Nicola Pietro Montaldo in discovering the Parkinson’s Biomarkers (Photo courtesy of Chalmers University of Technology)

Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests

Parkinson’s disease is a slow-progressing neurological disorder that disrupts the brain’s ability to control movement and is typically diagnosed after the age of 55. By the time motor symptoms appear,... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Noul’s AI-based cervical cancer diagnostic solution, miLab CER (Photo courtesy of Noul)

AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America

Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.